Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nomacopan in Pediatric HSCT-TMA
NCT04784455Phase 3Terminated
- Sponsor
- Akari Therapeutics
- Start
- Feb 2021
- Primary completion
- May 2024
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 3
01
Overview
A Phase 3 trial of nomacopan in thrombotic microangiopathy (TMA), sponsored by Akari Therapeutics. Started Feb 2021; status: terminated.
02
Drugs
nomacopan
03
Conditions
thrombotic microangiopathy (TMA)
Beyond the preview
Go deeper on NCT04784455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04784455.